These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35704250)

  • 1. Pharmacokinetics and Pharmacodynamic Effect of a Blood-Brain Barrier-Crossing Fusion Protein Therapeutic for Alzheimer's Disease in Rat and Dog.
    Lessard E; Rennie K; Haqqani A; Ling B; Whitfield J; Paradis A; Araujo J; Yoganathan N; Gillard J; Stanimirovic D; Chakravarthy B
    Pharm Res; 2022 Jul; 39(7):1497-1507. PubMed ID: 35704250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical
    Kang MS; Shin M; Ottoy J; Aliaga AA; Mathotaarachchi S; Quispialaya K; Pascoal TA; Collins DL; Chakravarty MM; Mathieu A; Sandelius Å; Blennow K; Zetterberg H; Massarweh G; Soucy JP; Cuello AC; Gauthier S; Waterston M; Yoganathan N; Lessard E; Haqqani A; Rennie K; Stanimirovic D; Chakravarthy B; Rosa-Neto P
    J Cereb Blood Flow Metab; 2022 May; 42(5):788-801. PubMed ID: 34378436
    [No Abstract]   [Full Text] [Related]  

  • 3. Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease.
    Chang R; Knox J; Chang J; Derbedrossian A; Vasilevko V; Cribbs D; Boado RJ; Pardridge WM; Sumbria RK
    Mol Pharm; 2017 Jul; 14(7):2340-2349. PubMed ID: 28514851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion of hIgG1-Fc to 111In-anti-amyloid single domain antibody fragment VHH-pa2H prolongs blood residential time in APP/PS1 mice but does not increase brain uptake.
    Rotman M; Welling MM; van den Boogaard ML; Moursel LG; van der Graaf LM; van Buchem MA; van der Maarel SM; van der Weerd L
    Nucl Med Biol; 2015 Aug; 42(8):695-702. PubMed ID: 25960433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel platform for engineering blood-brain barrier-crossing bispecific biologics.
    Farrington GK; Caram-Salas N; Haqqani AS; Brunette E; Eldredge J; Pepinsky B; Antognetti G; Baumann E; Ding W; Garber E; Jiang S; Delaney C; Boileau E; Sisk WP; Stanimirovic DB
    FASEB J; 2014 Nov; 28(11):4764-78. PubMed ID: 25070367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease.
    Yoshida K; Moein A; Bittner T; Ostrowitzki S; Lin H; Honigberg L; Jin JY; Quartino A
    Alzheimers Res Ther; 2020 Jan; 12(1):16. PubMed ID: 31969177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sialic acid (SA)-modified selenium nanoparticles coated with a high blood-brain barrier permeability peptide-B6 peptide for potential use in Alzheimer's disease.
    Yin T; Yang L; Liu Y; Zhou X; Sun J; Liu J
    Acta Biomater; 2015 Oct; 25():172-83. PubMed ID: 26143603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that a synthetic amyloid-ß oligomer-binding peptide (ABP) targets amyloid-ß deposits in transgenic mouse brain and human Alzheimer's disease brain.
    Chakravarthy B; Ito S; Atkinson T; Gaudet C; Ménard M; Brown L; Whitfield J
    Biochem Biophys Res Commun; 2014 Mar; 445(3):656-60. PubMed ID: 24569075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic Modeling of Soluble Aβ Dynamics and Target Engagement in the Brain by Anti-Aβ mAbs in Alzheimer's Disease.
    Ferl GZ; Fuji RN; Atwal JK; Sun T; Ramanujan S; Quartino AL
    Curr Alzheimer Res; 2020; 17(4):393-406. PubMed ID: 32116192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced neprilysin-mediated degradation of hippocampal Aβ42 with a somatostatin peptide that enters the brain.
    Rofo F; Ugur Yilmaz C; Metzendorf N; Gustavsson T; Beretta C; Erlandsson A; Sehlin D; Syvänen S; Nilsson P; Hultqvist G
    Theranostics; 2021; 11(2):789-804. PubMed ID: 33391505
    [No Abstract]   [Full Text] [Related]  

  • 11. Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain.
    Zhou QH; Fu A; Boado RJ; Hui EK; Lu JZ; Pardridge WM
    Mol Pharm; 2011 Feb; 8(1):280-5. PubMed ID: 21141969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).
    Do TM; Dodacki A; Alata W; Calon F; Nicolic S; Scherrmann JM; Farinotti R; Bourasset F
    J Alzheimers Dis; 2016; 49(2):287-300. PubMed ID: 26484906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides.
    Xiong H; Callaghan D; Jones A; Bai J; Rasquinha I; Smith C; Pei K; Walker D; Lue LF; Stanimirovic D; Zhang W
    J Neurosci; 2009 Apr; 29(17):5463-75. PubMed ID: 19403814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide.
    Sumbria RK; Hui EK; Lu JZ; Boado RJ; Pardridge WM
    Mol Pharm; 2013 Sep; 10(9):3507-13. PubMed ID: 23924247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
    Izzo NJ; Yuede CM; LaBarbera KM; Limegrover CS; Rehak C; Yurko R; Waybright L; Look G; Rishton G; Safferstein H; Hamby ME; Williams C; Sadlek K; Edwards HM; Davis CS; Grundman M; Schneider LS; DeKosky ST; Chelsky D; Pike I; Henstridge C; Blennow K; Zetterberg H; LeVine H; Spires-Jones TL; Cirrito JR; Catalano SM
    Alzheimers Dement; 2021 Aug; 17(8):1365-1382. PubMed ID: 33559354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.
    Hey JA; Kocis P; Hort J; Abushakra S; Power A; Vyhnálek M; Yu JY; Tolar M
    CNS Drugs; 2018 Sep; 32(9):849-861. PubMed ID: 30076539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.
    Shackleton B; Crawford F; Bachmeier C
    Fluids Barriers CNS; 2016 Aug; 13(1):14. PubMed ID: 27503326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oleocanthal enhances amyloid-β clearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model.
    Qosa H; Batarseh YS; Mohyeldin MM; El Sayed KA; Keller JN; Kaddoumi A
    ACS Chem Neurosci; 2015 Nov; 6(11):1849-59. PubMed ID: 26348065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease.
    Manczak M; Mao P; Nakamura K; Bebbington C; Park B; Reddy PH
    Hum Mol Genet; 2009 Oct; 18(20):3876-93. PubMed ID: 19617638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice.
    Abdallah IM; Al-Shami KM; Yang E; Kaddoumi A
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.